Sleep Apnea News and Research

RSS

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

Cortex Pharmaceuticals, Inc. announced that the rights to a published patent application entitled, "Pharmacological Modulation of Positive AMPA Receptor Modulator Effects on Neurotrophin Expression", has been licensed exclusively to Cortex from the University of California.

7 Oct 2010

ESH and ERS consent document to manage hypertension and OSA

Consensus document on the management of patients with obstructive sleep apnea and hypertension. Joint recommendations by The European COST Action B26, The European Society of Hypertension and The European Respiratory Society.

7 Oct 2010

Researchers explore changes in brain regions to combat sleep apnea

According to the National Heart, Lung and Blood Institute, the average sleep apnea sufferer stops breathing and loses oxygen between five and 30 times a night. This lack of oxygen leads to a host of complications, including high blood pressure, vascular disease, an abnormal heart rhythm, or even a fatal cardiac event. Now, a team of University of Missouri researchers is exploring the changes in distinct brain regions that contribute to these symptoms in hopes of combating this common health issue.

5 Oct 2010

Nasal CPAP machine may cause craniofacial changes

The use of a nasal continuous positive airway pressure (nCPAP) machine for more than 2 years may cause craniofacial changes in adults with obstructive sleep apnea (OSA).

5 Oct 2010

VIVUS announces divestiture of MUSE to Meda

VIVUS, Inc. today announced that it has entered into an asset purchase agreement with Meda - an international specialty pharma company - for MUSE®, transurethral alprostadil, for the treatment of erectile dysfunction (ED). Under the agreement, Meda will acquire the MUSE assets including the United States and foreign MUSE patents, existing inventory and the manufacturing facility located in Lakewood, New Jersey.

4 Oct 2010

J&JPRD receives FDA Complete Response Letter for tapentadol ER tablets NDA

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for tapentadol extended release tablets.

4 Oct 2010

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Cortex Pharmaceuticals, Inc. announced that it has regained worldwide rights to develop and commercialize its AMPAKINE® compounds for the treatment of schizophrenia and depression.

1 Oct 2010

Study examines link between insufficient sleep and blood pressure among pregnant women

A study in the Oct. 1 issue of the journal Sleep found that getting too little or too much sleep in early pregnancy is associated with elevated blood pressure in the third trimester. The study suggests that improving prenatal sleep hygiene may provide important health benefits.

1 Oct 2010

Adequate sleep is the secret to a long life

A new study, derived from novel sleep research conducted by University of California, San Diego researchers 14 years earlier, suggests that the secret to a long life may come with just enough sleep. Less than five hours a night is probably not enough; eight hours is probably too much.

1 Oct 2010

Rotech Healthcare prices $230 million Senior Secured Notes offering

Rotech Healthcare Inc. announced today the pricing of its offering of $230 million in aggregate principal amount of Senior Secured Notes due 2015. The notes will be sold to investors at a price of 97.189% of the principal amount thereof and will bear a coupon rate equal to 10 ¾ % per annum. The offering is expected to close on October 6, 2010.

30 Sep 2010

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic low back pain have been published online by Expert Opinion on Pharmacotherapy. In addition, this study compared oxycodone controlled-release (CR) to placebo as an active control.

28 Sep 2010

Rotech Healthcare offers $225 million in Senior Secured Notes due 2015

Rotech Healthcare Inc. announced today that the company intends to offer, subject to market and other conditions, $225 million in aggregate principal amount of Senior Secured Notes due 2015.

27 Sep 2010

UC San Diego receives grant to study hypoxia susceptibility

Gabriel G. Haddad, MD, chair of the Department of Pediatrics at the University of California, San Diego School of Medicine and Physician-in-Chief at Rady Children's Hospital-San Diego has received a $10 million grant from the National Institute of Health's Heart, Lung and Blood Institute.

24 Sep 2010

ImThera Medical releases interim results of clinical study on neurostimulation device for treating OSA

ImThera Medical, Inc. today announced interim results from its OSA European clinical study. For the study, ten patients have been surgically implanted with ImThera's aura6000 hypoglossal nerve neurostimulation device for treating Obstructive Sleep Apnea. The target population for ImThera's neurostimulation device is moderate and severe OSA patients who are non-compliant with or cannot tolerate Continuous Positive Airway Pressure.

22 Sep 2010

VIVUS announces QNEXA study results for obesity treatment

VIVUS, Inc. today announced positive top-line results from a two-year study of QNEXA(phentermine/topiramate) Controlled Release Capsules, an investigational therapy for treatment of obesity, a condition that affects approximately one-third of adult Americans.

21 Sep 2010

Bruner to encourage FDA advisory committee to consider effectiveness of obesity drug Lorcaserin

On September 16, Denise Bruner, MD, FASBP will speak in favor of FDA approval for the new obesity drug Lorcaserin, during the open public hearing hour at the Endocrinologic and Metabolic Drug Advisory Committee meeting.

15 Sep 2010

Somaxon's Silenor now commercially available in U.S.

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that Silenor® (doxepin) now is commercially available by prescription in the United States. Somaxon has implemented a wholesale and retail stocking program to disseminate Silenor 3 mg and 6 mg dosepacks to pharmacies across the United States. Silenor is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

7 Sep 2010

Chronic insomnia with objectively measured short sleep duration associated with increased mortality in men

A study in the Sept. 1 issue of the journal SLEEP found an elevated risk of death in men with a complaint of chronic insomnia and an objectively measured short sleep duration. The results suggest that public health policy should emphasize the diagnosis and appropriate treatment of chronic insomnia.

2 Sep 2010

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation.

31 Aug 2010

Victhom second-quarter revenues decrease 94.4% to $27,901

Victhom Human Bionics Inc. today reported its second quarter 2010 financial results.

27 Aug 2010

Sleep Apnea News and Research

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

ESH and ERS consent document to manage hypertension and OSA

Researchers explore changes in brain regions to combat sleep apnea

Nasal CPAP machine may cause craniofacial changes

VIVUS announces divestiture of MUSE to Meda

J&JPRD receives FDA Complete Response Letter for tapentadol ER tablets NDA

Cortex regains global rights to AMPAKINE compounds for treatment of schizophrenia and depression

Study examines link between insufficient sleep and blood pressure among pregnant women

Adequate sleep is the secret to a long life

Rotech Healthcare prices $230 million Senior Secured Notes offering

PGIC analysis indicates tapentadol ER tablets provide significant improvement in pain intensity

Rotech Healthcare offers $225 million in Senior Secured Notes due 2015

UC San Diego receives grant to study hypoxia susceptibility

ImThera Medical releases interim results of clinical study on neurostimulation device for treating OSA

VIVUS announces QNEXA study results for obesity treatment

Bruner to encourage FDA advisory committee to consider effectiveness of obesity drug Lorcaserin

Somaxon's Silenor now commercially available in U.S.

Chronic insomnia with objectively measured short sleep duration associated with increased mortality in men

Tapentadol ER improves average intensity of chronic osteoarthritis knee pain: Study

Victhom second-quarter revenues decrease 94.4% to $27,901

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News